Arax Advisory Partners’s Edgewise Therapeutics EWTX Stock Holding History

Arax Advisory Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07K	Buy	+51	New	+$1.76K	﹤0.01%	4806
2026 Q1	–	Sell	-87	Closed	-$2.16K	–	3973
2025 Q4	$2.16K	Sell	87 -19	-18%	-$381	﹤0.01%	3232
2025 Q3	$1.72K	Buy	106 +58	+121%	+$823	﹤0.01%	3148
2025 Q2	$630	Buy	+48	New	+$692	﹤0.01%	2898
2025 Q1	–	Sell	-75	Closed	-$2K	–	2802
2024 Q4	$2K	Sell	75 -23	-23%	-$732	﹤0.01%	2013
2024 Q3	$2.62K	Hold	98	–	–	﹤0.01%	1962
2024 Q2	$1.76K	Buy	+98	New	+$1.71K	﹤0.01%	2009

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's EWTX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 51 shares worth $2.07K. The stake represents ﹤0.01% of the portfolio and ranks #4806 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in EWTX as recently as Q4 2025.

Arax Advisory Partners first reported a position in EWTX in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.62K in Q3 2024. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Arax Advisory Partners held 51 shares of Edgewise Therapeutics worth $2.07K as of Q2 2026.
Edgewise Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Edgewise Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4806 holding.
Arax Advisory Partners first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Edgewise Therapeutics position peaked at $2.62K in Q3 2024.
225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.